VivoSense Exits Stealth Mode with a Big Series A Round

VivoSense is coming out of stealth mode and making a loud statement with a $25 million series A financing.

The Newport Beach, CA-based company is designing a platform to deliver real-world digital clinical measures from wearable sensors. The goal of the VivoSense platform is to advance patient-focused drug development and precision medicine for patients with cancer, Alzheimer’s, rare disease, and other therapeutic indications.

The technology allows rigorous interpretation of subtle shifts in human physiology through customized, body-worn monitoring and analysis solutions rooted in scientific foundations.

“True to our name, using our proprietary software, VivoSense “makes sense” of the myriad of biological signals that make up a patient’s physiology,” VivoSense CEO, Dudley Tabakin told MD+DI. “These include physical activity, sleep, temperature, blood-glucose levels, respiration, and cardiac function. VivoSense’s platform can be used to support clinical trials across key therapeutic areas, including oncology, neurodegenerative diseases, cardiorespiratory conditions, and rare diseases.

The financing was from the Debiopharm Innovation Fund and the Perceptive Xontogeny Venture (PXV) Fund. VivoSense will use this financing to expand and refine its informatics platform for data analysis from wearable and connected technologies to deliver validated digital clinical outcome assessments (COAs) for lifescience research.

“We are fortunate to have the Perceptive Xontogeny Venture (PXV) Fund and Debiopharm Innovation Fund co-lead this investment and Chris Garabedian and Tanja Dowe join our Board of Directors,” Tabakin said. “Both are believers in our platform and its potential to bring substantial value to a broad range of clinical research applications to enable patient-focused drug development efforts. They also recognize the important role that data captured by wearable sensors will play in the biotechnology industry and the capturing of real-world patient data.”